AstraZeneca Announces Completion Of Exclusive License Agreement With Dizal Pharmaceutical For Worldwide Rights To ZEGFROVY For $600M Upfront, Up To $900M In Milestones, Plus Tiered Royalties; US Launch Planned Q4 2026
Share
Why It Matters
AstraZeneca bought the worldwide rights to sell a medicine called ZEGFROVY for $600 million upfront, with more money to come if it succeeds. This shows the company is betting on a new drug to help patients, which is a sign they're working to grow their medicine collection.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.